IRS Denies Tax-Exempt Status to PTSD Veteran Therapy Program Over Ayahuasca Use

IRS Rejects 501(c)(3) Exemption for Veteran PTSD Program Over Ayahuasca Requirement

The IRS has denied tax-exempt status to a nonprofit organization that sought to treat veterans with post-traumatic stress disorder (PTSD) through supervised ayahuasca ceremonies, citing the organization’s requirement that participants ingest a Schedule I controlled substance under federal law. The ruling, issued as a non-precedential Private Letter Ruling (PLR), underscores the agency’s strict enforcement of public policy prohibitions against illegal drug use, even in therapeutic or religious contexts. The decision signals heightened scrutiny for nonprofits incorporating alternative therapies involving controlled substances, raising questions about the viability of such programs under Section 501(c)(3) of the Internal Revenue Code.

The Question: Can a PTSD Therapy Program for Veterans Qualify for 501(c)(3) Exemption?

The taxpayer sought recognition of exemption under Section 501(c)(3) of the Internal Revenue Code for a nonprofit organization operating a PTSD therapy program for military veterans. The organization’s stated purpose was to provide charitable relief to combat veterans suffering from post-traumatic stress disorder (PTSD) through a structured, 90-day immersive therapeutic deployment program. The program blended certified adventure therapy activities—such as skydiving, scuba diving, and motorsports—with licensed trauma-informed clinical care and peer support networks.

The organization’s application emphasized its exclusive focus on veterans, asserting that the program would be provided free of charge to participants, funded entirely through charitable donations. The IRS filing described the program as designed to reduce suicide risk, foster resilience, and help veterans process trauma and rediscover purpose through structured, high-impact outdoor and adventure-based interventions. The organization’s articles of incorporation and governing documents limited its activities to these stated charitable purposes, asserting compliance with the organizational test under Section 501(c)(3).

The IRS’s subsequent denial of the exemption hinged not on the program’s charitable intent or veteran-focused mission, but on the inclusion of a Schedule I controlled substance as a non-negotiable program requirement—a fact not disclosed in the initial exemption request but later revealed in the factual record.

The Facts: Ayahuasca as a Non-Negotiable Program Requirement

The organization’s exemption application disclosed that veterans seeking PTSD treatment would be required to participate in supervised ayahuasca ceremonies as a core program component. According to the factual record, the organization explicitly stated that participants must possess a valid passport for international travel and demonstrate willingness to engage in these ceremonies, which it described as lawfully conducted abroad by trained professionals. The IRS noted that the organization asserted it would not administer, transport, manufacture, or handle any controlled substances in the U.S. or any other country.

The record further reveals that ayahuasca contains dimethyltryptamine (DMT), a Schedule I controlled substance under the Controlled Substances Act (CSA), 21 U.S.C. § 812(c)(1), which prohibits its use without a valid federal exemption. Despite this legal prohibition, the organization did not provide proof of any exemption granted under the CSA, including a religious exemption under the Religious Freedom Restoration Act (RFRA) or a research exemption under 21 U.S.C. § 823(f). The IRS found the organization’s responses to subsequent requests for additional information inadequate, particularly regarding the lack of documentation demonstrating compliance with federal drug laws.

The Ruling: IRS Denies Exemption Due to Illegal Substance Use

The IRS concluded that the organization fails the operational test under Treas. Reg. § 1.501(c)(3)-1(c)(1), which requires that a § 501(c)(3) organization operate exclusively for exempt purposes. The regulation specifies that an organization’s activities must further one or more of the statutorily permitted purposes—such as charitable, educational, or religious goals—without serving private interests or violating public policy. The IRS determined that the organization’s requirement of ayahuasca participation, a Schedule I controlled substance under 21 U.S.C. § 812(c), contravenes federal law and disqualifies it from meeting this standard.

The IRS rejected the organization’s argument that its activities were exempt under the Religious Freedom Restoration Act (RFRA) or conducted under a valid research exemption under 21 U.S.C. § 823(f), noting the absence of any documentation proving compliance with the Controlled Substances Act (CSA). The agency emphasized that Rev. Rul. 71-460 bars organizations from qualifying for exemption if their foreign activities would violate U.S. law, even if those activities are legal in the host country. Because the organization’s primary activity—supervised ayahuasca ceremonies—requires the use of an illegal substance, the IRS held that it cannot operate exclusively for exempt purposes. The IRS concluded: “Therefore, by generally requiring participation in a supervised ayahuasca ceremony, which involves a controlled substance illegal under U.S. law, you are not operating exclusively for exempt purposes as required by Treas. Reg. § 1.501(c)(3)-1(c)(1).” Accordingly, the organization does not qualify for § 501(c)(3) exemption.

The Rationale: Public Policy and the Controlled Substances Act

The IRS grounded its denial in the Controlled Substances Act (CSA), 21 U.S.C. § 812(c), which classifies ayahuasca’s psychoactive compounds (DMT and harmaline) as Schedule I substances. Schedule I drugs are defined as having no accepted medical use in the United States and a high potential for abuse, making their manufacture, distribution, or possession illegal without a specific federal exemption. The organization did not provide evidence of such an exemption from the Drug Enforcement Administration (DEA), which is required under 21 U.S.C. § 823(f) for any lawful use of controlled substances.

Even if the ayahuasca ceremonies occurred abroad, the IRS cited Rev. Rul. 71-460, which holds that U.S. tax-exempt status under IRC § 501(c)(3) requires compliance with U.S. public policy, not foreign law. The ruling states that an organization’s activities must qualify for exemption under U.S. standards, regardless of where they take place. The IRS reinforced this principle with Rev. Rul. 75-384, which denies tax-exempt status to organizations engaged in activities illegal under U.S. law, even if those activities are permitted in another country. The IRS explicitly rejected the argument that foreign legality could override domestic drug laws, stating: “Even if activities are conducted internationally, it is not the laws of those countries which control for federal tax exemption purposes; it is the laws of the U.S.”

The IRS also relied on Rev. Rul. 80-278, which clarifies that an organization’s primary activity must further an exempt purpose—not a non-exempt one. Here, the IRS determined that the core of the organization’s operations—supervised ayahuasca ceremonies—constituted a substantial non-exempt purpose because it involved the use of an illegal controlled substance. The IRS quoted the operational test under Treas. Reg. § 1.501(c)(3)-1(c)(1), which requires that an organization operate exclusively for exempt purposes, and concluded that the requirement to participate in ayahuasca ceremonies violated this standard.

The decision cited Iowaska Church of Healing v. Werfel (2024), a federal court case in which the U.S. District Court for the District of Columbia upheld the IRS’s denial of tax-exempt status for a church using ayahuasca. In that case, the court ruled that RFRA (the Religious Freedom Restoration Act) did not shield the church from CSA enforcement, as the government demonstrated a compelling interest in preventing Schedule I drug use. The IRS applied this precedent directly, noting that the organization failed to demonstrate any legal basis for its ayahuasca use and thus could not satisfy the operational test for § 501(c)(3) status. The IRS concluded: “Participation in ayahuasca ceremonies is illegal on its face without an exemption issued by a federal authority or other permitting agency.” Without proof of such an exemption, the organization’s activities were deemed to contravene federal law, disqualifying it from tax-exempt status.

Implications: What This Means for Nonprofits and Alternative Therapies

The IRS’s denial of § 501(c)(3) status to the veteran PTSD program over its ayahuasca requirement signals a strict enforcement posture against nonprofits whose activities involve controlled substances, even when conducted abroad. The agency applied the operational test under § 501(c)(3), which requires organizations to engage exclusively in activities that further exempt purposes without violating public policy. The IRS concluded that the organization’s primary activity—facilitating ayahuasca ceremonies—violated the Controlled Substances Act (CSA), specifically 21 U.S.C. § 812(c), which classifies DMT (the psychoactive compound in ayahuasca) as a Schedule I substance with no accepted medical use. The IRS emphasized that participation in ayahuasca ceremonies is illegal on its face without a federal exemption, rendering the organization ineligible for tax-exempt status.

This ruling underscores the absolute bar on activities involving controlled substances for § 501(c)(3) organizations, regardless of religious or therapeutic intent. The IRS did not distinguish between domestic and foreign use, applying the same standard to ayahuasca ceremonies conducted in countries where the substance is legal. The agency’s reasoning relied on Rev. Rul. 75-384, which holds that organizations cannot engage in illegal activities abroad and retain tax-exempt status. The IRS further noted that the organization failed to demonstrate any legal basis for its ayahuasca use, leaving no room for exceptions under the Religious Freedom Restoration Act (RFRA) or other defenses.

For nonprofits in the veteran support or alternative therapy spaces, this decision creates a chilling effect on the incorporation of psychedelic-assisted therapies, even where such treatments show promise. Organizations considering programs involving controlled substances must now secure explicit federal exemptions—such as a DEA registration under 21 U.S.C. § 823(f) or a religious exemption under RFRA—before applying for § 501(c)(3) status. The IRS’s emphasis on thorough documentation and clarity in exemption applications is critical; vague or unsupported claims about legality will not suffice. Nonprofits must also ensure that any controlled substance use is incidental to their exempt purpose and not the primary activity, as the IRS will scrutinize commercialization risks.

The implications extend beyond ayahuasca to other alternative therapies involving Schedule I substances, such as psilocybin or MDMA. While research exemptions exist, nonprofits cannot assume that therapeutic use alone justifies tax-exempt status. The IRS’s position, as articulated in this ruling, demands ironclad proof of compliance with federal drug laws, including foreign operations. Organizations must also prepare for increased IRS scrutiny of their activities, particularly if they operate in jurisdictions where controlled substances are decriminalized or legal. Clear communication in exemption applications—detailing legal justifications, safety protocols, and the non-commercial nature of the activities—is now a prerequisite for approval.

This ruling is non-precedential, but its reasoning is instructive for future IRS determinations. Nonprofits in the veteran support or alternative therapy sectors should treat it as a warning to align their programs strictly with federal law or risk disqualification from tax-exempt status. The IRS’s message is unambiguous: no activity involving controlled substances is permissible under § 501(c)(3) without explicit federal authorization.